Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

  • Ruiz-Malagón, Antonio J.
  • Herraiz-Vilela, Marina
  • Pinazo-Bandera, José
  • Toro-Ortiz, Juan Pedro
  • López-Gómez, Carlos
  • Ho-Plagaro, Ailec
  • Garrido-Sánchez, Lourdes
  • Robles-Díaz, María Mercedes
  • Taminiau, Bernard
  • Daube, Georges
  • Sanabria-Cabrera, Judith
  • Matilla-Cabello, Gonzalo
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • García-Fuentes, Eduardo
  • García-Cortés, Miren
  • Rodríguez-Díaz, Cristina
The role of extracellular vesicles secreted by the gut microbiota present in faeces (fEVs) is not well known in metabolic dysfunction- associated steatotic liver disease (MASLD) and idiosyncratic drug-induced liver injury (DILI). We identify the microbiome profiles of fEVs in these liver diseases, and analyse the effects of fEVs from MASLD, without (F ≤ 2) or with (F ≥ 3) significant liver fibrosis, and DILI patients on inflammation, steatosis and mitochondrial function. DILI patients showed a consistent pattern in fEVs, characterised by a decrease in Paraprevotella and an increase in AAP99, Acinetobacter, Actinobacillus, Aerococcus and Anaeroglobus . A higher presence of 16S rDNA was observed in plasma EVs from MASLD and DILI patients. HepG2 cells treated with DILI and MASLD F ≥ 3 fEVs increased TLR4 , TLR5 , IL6 and CASP3 expression, and accumulation of lipid droplets. DILI fEVs enhanced the hepatotoxic impact of diclofenac on the response to microbial components ( TLR4 , TLR5 ), inflammatory response ( IL1B , IL6 ), accumulation of lipid droplets and mitochondrial dysfunction ( OPA1 , DNM1L ). In conclusion, bacterial EVs enter the bloodstream and could modulate the immune response. DILI and MASLD F ≥ 3 fEVs are drivers of the pro-inflammatory response and hepatocyte steatosis. DILI fEVs have a distinct bacterial profile that enhances the hepatotoxic potential of diclofenac., Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Consejería de Salud, Junta de Andalucía, European Comission, Ministerio de Ciencia, Innovación y Universidades
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Garcia-Cortes, Miren|||0000-0003-0410-8273
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Gonzalez-Jimenez, Andrés
  • Alvarez-Alvarez, Ismael
  • Slim, Mahmoud|||0000-0003-2455-1432
  • Jimenez-Perez, Miguel
  • Gonzalez-Grande, Rocio
  • Fernández, M.Carmen
  • Casado, Marta
  • Soriano, German|||0000-0002-9267-6811
  • Roman, Eva|||0000-0001-9084-8555
  • Hallal, Hacibe
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Castiella, Agustin
  • Conde, Isabel|||0000-0001-7863-2233
  • Prieto, Martin
  • Moreno-Planas, Jose Maria
  • Giraldez, Alvaro
  • Moreno-Sanfiel, J.Miguel
  • Kaplowitz, Neil
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Cortés, M.G.
  • Pinazo, Jose
  • García Muñoz, B.
  • Alcántara, Ramiro
  • Hernández, Andrés
  • Escaño, M.D.García
  • del Campo, E.
  • González-Jiménez, A.
  • Sanjuán Jiménez, Rocío
  • Cueto, Alejandro
  • Bonilla, Elvira
  • Di Zeo, D.
  • Niu, H.
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Papineau, A.
  • Pérez Hernández, Manuel José
  • González-Grande, Rocío|||0000-0002-7691-5755
  • López Ortega, S.
  • Santaella, I.
  • Ocaña, A.
  • Palomino, P.
  • Fernández, Maria Carmen
  • Peláez, Gloria
  • Porcel, A.
  • Casado, M.
  • González Sánchez, Mara
  • Millán-Domínguez, R.
  • Fombuena, Blanca
  • Gallego, Rocío
  • Ampuero, Javier|||0000-0002-8332-2122
  • Del Campo, José Antonio
  • Calle-Sanz, R.
  • Rojas, Lourdes
  • Rojas, Ángela|||0000-0003-0853-4800
  • Gil Gómez, Alexandra
  • Vilar, Eduardo
  • Guarner, Carlos|||0000-0001-5957-9481
  • Quijada-Manuitt, María Ángeles|||0000-0002-9624-0177
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Vergara Gómez, Mariano
  • Hallal, H.
  • García Oltra, Ester
  • Titos Arcos, J.C.
  • Pérez Martínez, Alfonso
  • Sánchez Cobarro, C.
  • Egea Caparrós, J.M.
  • Zapata, Eva María
  • Arenas, Juan Ignacio
  • Gómez García, Alexandra
  • Esandi, F.J.
  • Blanco, Sonia
  • Martínez Odriozola, Pedro
  • Crespo García, Javier|||0000-0001-8248-0172
  • Iruzubieta, Paula|||0000-0001-9476-1801
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • Giráldez Gallego, Álvaro
  • Rodríguez Seguel, Elisa
  • Cuaresma, María
  • González-Gallego, Javier|||0000-0002-4386-9342
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Sánchez Campos, S.
  • Otazua, Pedro
  • de Juan Gómez, A.
  • Salmerón, Javier
  • Gila, Ana
  • Quiles, Rosa
  • González, José Manuel
  • Lorenzo, Sara
  • Prieto, Martín
  • Conde Amiel, I.
  • Berenguer, Marina|||0000-0001-9246-4264
  • García-Eliz, María
  • Primo, Joaquín
  • Molés, José Ramón
  • Garayoa, Ana
  • Carrascosa, Miguel
  • Gómez Domínguez, Elena
  • Cuevas, L.
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Montané Esteva, Eva|||0000-0002-1691-7652
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Arellano, Ana Lucía|||0000-0001-8601-3504
  • Sanz, Yolanda
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Sala, Margarita
  • Masnou Ridaura, H.
  • Bruguera, Miquel
  • Ginès, Pere|||0000-0003-4657-4504
  • Lens, Sabela|||0000-0003-4900-411X
  • Mariño, Zoe|||0000-0001-6321-9534
  • Hernández Guerra, Manuel
  • Moreno Sanfiel, J.M.
  • Fernández del Campo, C.Boada
  • Tejedor, Martián
  • González Ferrer, Ruth
  • Fernández, Conrado
  • Fernández Gil, Marta
  • Montero, José Luís
  • de la Mata, Manuel
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Fernández Bonilla, E.M.
  • Moreno, Julián M.
  • Martínez-Ródenas, Ponciano
  • Gómez Garrido, M.
  • Oliva, C.
  • Rendón, Paloma|||0000-0002-6521-3766
  • García Samaniego, Javier
  • Madejón, Antonio
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Martínez Porras, J.L.
  • Cabriada, José Luis|||0000-0002-3068-5659
  • Pérez-Moreno, José Manuel
  • Lara, Carmen
Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes.